Researchers from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have presented NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of neurodegeneration.

Suzhou Zion Pharma Technology Co. Ltd. has identified GTPase KRAS G12D or G13D mutant and/or KRAS inhibitors reported to be useful for the treatment of cancer.

Shenzhen Zhongge Biotechnology Co. Ltd. has synthesized AMP-activated protein kinase α1β1γ1 activators reported to be useful for the treatment of acute kidney injury, alopecia, chronic kidney disease, diabetes type 2, diabetic nephropathy, dyslipidemia and obesity.

The University of Hong Kong has patented RNA polymerase β subunit/RNA polymerase sigma factor RpoD (bacterial) interaction inhibitors reported to be useful for the treatment of gram-positive bacterial infections.

Kymera Therapeutics Inc. has described proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a signal transducer and activator of transcription 6 (STAT6)-targeting moiety.

Maze Therapeutics Inc. has disclosed new sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of phenylketonuria, metabolic syndrome, hyperphenylalaninemia, tyrosinemia, isovaleric acidemia, propionic acidemia, maple syrup urine disease and chronic kidney disease, among others.

Work at Purdue Research Foundation has led to the identification of prodrugs of nicotinamide N-methyltransferase (NNMT) inhibitors reported to be useful for the treatment of cancer.

GTPase KRAS G12D mutant and/or G12V mutant inhibitors potentially useful for the treatment of cancer have been detailed in a Quanta Therapeutics Inc.

rietis Corp. and St. Jude Children’s Research Hospital Inc. have jointly patented compounds acting as caseinolytic protease P (ClpP) (bacterial) activators and RNA polymerase (bacterial) inhibitors and their conjugates with rifamycin analogues reported to be useful for the treatment of gram-positive bacterial infection.

Patents from Oncopia Therapeutics Inc. (dba SK Life Science Labs) describe proteolysis targeting chimeric (PROTACs) compounds reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.